In Section A, participants will obtain distinctive doses and schedules of oral ABBV-744 pill to recognize safe dosing regimen. More contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://judahyjteo.pointblog.net/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described-74640056